Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era

Briefings in Bioinformatics

Volumn 18, Issue 4, 2017, Pages 682-697

  Cheng, Feixiong ^a,b   Hong, Huixiao ^c   Yang, Shengyong ^d   Wei, Yuquan ^d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c NANJING UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Cancer genomics; Drug repositioning; Panomics; Precision oncology; Systems biology; Systems pharmacology

Indexed keywords

DRUG REPOSITIONING; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; NEOPLASM; PERSONALIZED MEDICINE;

DRUG REPOSITIONING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PRECISION MEDICINE;

EID: 85027108338     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbw051     Document Type: Article

References (181)

1. Scannell JW, Blanckley A, Boldon H, et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012;11:191-200
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14
3. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83
4. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6
5. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 2011;3:96ra76
6. Stenvang J, Kumler I, Nygard SB, et al. Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol 2013;3:313
7. International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010;464:993-8
8. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011;17:297-303
9. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013;339:1546-58
10. Cheng F, Zhao J, Zhao Z. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief Bioinform 2015; doi: 10. 1093/bib/bbv068
11. Cheng F, Liu C, Lin CC, et al. A gene gravity model for the evolution of cancer genomes: a study of 3, 000 cancer genomes across 9 cancer types. PLoS Comput Biol 2015;11:e1004497
12. Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015;519:102-5
13. Zhang Z, Stiegler AL, Boggon TJ, et al. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 2010;1:497-514
14. Menzies AM, Long GV, Murali R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 2012;6:391-405
15. Schork NJ. Personalized medicine: time for one-person trials. Nature 2015;520:609-11
16. Cheng F, Jia P, Wang Q, et al. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. Oncotarget 2014;5:3697-710
17. Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov 2015;14:513-5
18. Sirota M, Dudley JT, Kim J, et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 2011;3:96ra77
19. Wu Z, Cheng F, Li J, et al. SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drugtarget interactions and drug repositioning. Brief Bioinform 2016; doi: 10. 1093/bib/bbw012
20. Cheng F, Zhou Y, Li W, et al. Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One 2012;7:e41064
21. Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol 2015;12:732-42
22. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-11
23. Elbaz HA, Stueckle TA, Tse W, et al. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012;1:4
24. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37
25. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. 2007;297:267-77
26. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77
27. Aftab BT, Dobromilskaya I, Liu JO, et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71:6764-72
28. Lockhart NR, Waddell JA, Schrock NE. Itraconazole therapy in a pancreatic adenocarcinoma patient: a case report. J Oncol Pharm Pract 2015;22:528-32
29. Liu R, Li J, Zhang T, et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy 2014;10:1241-55
30. Antonarakis ES, Heath EI, Smith DC, et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013;18:163-73
31. Quinn BJ, Kitagawa H, Memmott RM, et al. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab 2013;24:469-80
32. Kumar S, Meuter A, Thapa P, et al. Metformin intake is associated with better survival in ovarian cancer: a case-control study. Cancer 2013;119:555-62
33. Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953-66
34. Mayer MJ, Klotz LH, Venkateswaran V. Metformin and prostate cancer stem cells: a novel therapeutic target. Prostate Cancer Prostatic Dis 2015;18:303-9
35. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11
36. Jahchan NS, Dudley JT, Mazur PK, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 2013;3:1364-77
37. Lu W, Cheng F, Jiang X, et al. Medical genetics-based repusposing identifies an antidepressant drug, sertraline, that overcomes resistance of erlotinib through induction of autophagy in non-small cell lung cancer. Autophagy 2016; under review
38. Shchors K, Massaras A, Hanahan D. Dual targeting of the autophagic regulatory circuitry in gliomas with repurposed drugs elicits cell-lethal autophagy and therapeutic benefit. Cancer Cell 2015;28:456-71
39. Zhou H, Liu W, Su Y, et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 2010;17:560-73
40. Cheng F, Liu C, Jiang J, et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 2012;8:e1002503
41. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606
42. Jendrossek V. Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett 2013;332:313-24
43. Brandao RD, Veeck J, Van de Vijver KK, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013;15:R29
44. Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 2015;7:277ra30
45. Galluzzi L, Buque A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 2015;28:690-714
46. Lauriola M, Enuka Y, Zeisel A, et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat Commun 2014;5:5073
47. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59
48. Wang Q, Jia P, Cheng F, et al. Heterogeneous DNA methylation contributes to tumorigenesis through inducing the loss of coexpression connectivity in colorectal cancer. Genes Chromosomes Cancer 2015;54:110-21
49. Gonzalez-Perez A, Mustonen V, Reva B, et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods 2013;10:723-9
50. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1
51. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015;43:D805-11
52. Zhu Y, Qiu P, Ji Y. TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods 2014;11:599-600
53. Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 2016;44:e71. doi: 10. 1093/nar/gkv1507
54. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7
55. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51
56. Andersson R, Gebhard C, Miguel-Escalada I, et al. An atlas of active enhancers across human cell types and tissues. Nature 2014;507:455-61
57. Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74
58. Roadmap Epigenomics C, Kundaje A, Meuleman W, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317-30
59. Consortium GT., Human genomics The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648-60
60. Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580-5
61. Li J, Lu Y, Akbani R, et al. TCPA: a resource for cancer functional proteomics data. Nat Methods 2013;10:1046-7
62. Ellis MJ, Gillette M, Carr SA, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI clinical proteomic tumor analysis consortium. Cancer Discov 2013;3:1108-12
63. Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature 2014;513:382-7
64. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006
65. Law V, Knox C, Djoumbou Y, et al. DrugBank 4. 0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42:D1091-7
66. Yang H, Qin C, Li YH, et al. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res 2016;44:D1069-74
67. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40:D1100-7
68. Liu T, Lin Y, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198-201
69. Hewett M, Oliver DE, Rubin DL, et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res 2002;30:163-5
70. Szklarczyk D, Santos A, von Mering C, et al. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 2016;44:D380-4
71. Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 2009;37:W623-33
72. von Eichborn J, Murgueitio MS, Dunkel M, et al. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2011;39:D1060-6
73. Bulusu KC, Tym JE, Coker EA, et al. canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 2014;42:D1040-7
74. Wagner AH, Coffman AC, Ainscough BJ, et al. DGIdb 2. 0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 2016;44:D1036-44
75. Liu X, Wang S, Meng F, et al. SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression. Bioinformatics 2013;29:409-11
76. Rukov JL, Wilentzik R, Jaffe I, et al. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 2014;15:648-59
77. Meng F, Wang J, Dai E, et al. Psmir: a database of potential associations between small molecules and miRNAs. Sci Rep 2016;6:19264
78. Jiang W, Chen X, Liao M, et al. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Sci Rep 2012;2:282
79. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35
80. Duan Q, Flynn C, Niepel M, et al. LINCS canvas browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 2014;42:W449-60
81. Adams JU. Genetics: big hopes for big data. Nature 2015;527:S108-9
82. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41:D955-61
83. Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a webbased suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012;72:3499-511
84. Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015;5:1210-23
85. Abaan OD, Polley EC, Davis SR, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 2013;73:4372-82
86. Klijn C, Durinck S, Stawiski EW, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 2015;33:306-12
87. Gohlke BO, Nickel J, Otto R, et al. CancerResource-updated database of cancer-relevant proteins, mutations and interacting drugs. Nucleic Acids Res 2016;44:D932-7 doi: 10. 1093/nar/gkv1283
88. Zeng T, Zhang W, Yu X, et al. Big-data-based edge biomarkers: study on dynamical drug sensitivity and resistance in individuals. Brief Bioinform 2016; doi: 10. 1093/bib/bbv078
89. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res 2013;41:D816-23
90. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database-2009 update. Nucleic Acids Res 2009;37:D767-72
91. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013;41:D808-15
92. Cowley MJ, Pinese M, Kassahn KS, et al. PINA v2. 0: mining interactome modules. Nucleic Acids Res 2012;40:D862-5
93. Breuer K, Foroushani AK, Laird MR, et al. InnateDB: systems biology of innate immunity and beyond-recent updates and continuing curation. Nucleic Acids Res 2013;41:D1228-33
94. Mosca R, Ceol A, Aloy P. Interactome3D: adding structural details to protein networks. Nat Methods 2013;10:47-53
95. Hornbeck PV, Kornhauser JM, Tkachev S, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 2012;40:D261-70
96. Minguez P, Letunic I, Parca L, et al. PTMcode v2: a resource for functional associations of post-translational modifications within and between proteins. Nucleic Acids Res 2015;43:D494-502
97. Kanehisa M, Goto S, Sato Y, et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014;42:D199-205
98. Kelder T, van Iersel MP, Hanspers K, et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res 2012;40:D1301-7
99. Cerami EG, Gross BE, Demir E, et al. Pathway commons, a web resource for biological pathway data. Nucleic Acids Res 2011;39:D685-90
100. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013;41:D991-5
101. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6
102. Kim Kjaerulff S, Wich L, Kringelum J, et al. ChemProt-2. 0: visual navigation in a disease chemical biology database. Nucleic Acids Res 2013;41:D464-9
103. Croft D, Mundo AF, Haw R, et al. The reactome pathway knowledgebase. Nucleic Acids Res 2014;42:D472-7
104. Diella F, Cameron S, Gemund C, et al. Phospho. ELM: a database of experimentally verified phosphorylation sites in eukaryotic proteins. BMC Bioinformatics 2004;5:79
105. Doerks T, Copley RR, Schultz J, et al. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res 2002;12:47-56
106. Batagelj V, Mrvar A. Pajek-program for large network analysis. Connections 1998;21:47-57
107. Chen X, Yan CC, Zhang X, et al. Drug-target interaction prediction: databases, web servers and computational models. Brief Bioinform 2016; doi: 10. 1093/bib/bbv066
108. Liu Z, Fang H, Reagan K, et al. In silico drug repositioning: what we need to know. Drug Discov Today 2013;18:110-5
109. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19:637-44
110. Wu Z, Wang Y, Chen L. Network-based drug repositioning. Mol Biosyst 2013;9:1268-81
111. Zhao H, Jin G, Cui K, et al. Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases. Cancer Res 2013;73:6149-63
112. Jin G, Fu C, Zhao H, et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 2012;72:33-44
113. Gottlieb A, Stein GY, Ruppin E, et al. PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011;7:496
114. Woo JH, Shimoni Y, Yang WS, et al. Elucidating compound mechanism of action by network perturbation analysis. Cell 2015;162:441-51
115. Cheng F, Li W, Wang X, et al. Adverse drug events: database construction and in silico prediction. J Chem Inf Model 2013;53:744-52
116. Cheng F, LiW, ZhouY, et al. Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomicderivedmodels (PTDMs). Mol Biosyst 2013;9:1316-25
117. Cheng F, Zhou Y, Li J, et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol Biosyst 2012;8:2373-84
118. Zhang C, Hong H, Mendrick DL, et al. Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science. Biomark Med 2015;9:1241-52
119. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA 2010;107:14621-6
120. Ung MH, Varn FS, Cheng C. IDEA: integrated drug expression analysis-integration of gene expression and clinical data for the identification of therapeutic candidates. CPT Pharmacometrics Syst Pharmacol 2015;4:415-25
121. Amelio I, Gostev M, Knight RA, et al. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis 2014;5:e1051
122. Shigemizu D, Hu Z, Hung JH, et al. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol 2012;8:e1002347
123. Cheng F, Jia P, Wang Q, et al. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. Mol Biol Evol 2014;31:2156-69
124. Cukuroglu E, Engin HB, Gursoy A, et al. Hot spots in proteinprotein interfaces: towards drug discovery. Prog Biophys Mol Biol 2014;116:165-73
125. Duran-Frigola M, Mosca R, Aloy P. Structural systems pharmacology: the role of 3D structures in next-generation drug development. Chem Biol 20:674-84
126. Xie L, Ge X, Tan H, et al. Towards structural systems pharmacology to study complex diseases and personalized medicine. PLoS Comput Biol 2014;10:e1003554
127. Porta-Pardo E, Garcia-Alonso L, Hrabe T, et al. A pan-cancer catalogue of cancer driver protein interaction interfaces. PLoS Comput Biol 2015;11:e1004518
128. Ghersi D, Singh M. Interaction-based discovery of functionally important genes in cancers. Nucleic Acids Res 2014;42:e18
129. Vuong H, Cheng F, Lin CC, et al. Functional consequences of somatic mutations in cancer using protein pocket-based prioritization approach. Genome Med 2014;6:81
130. Zhao J, Cheng F, Wang Y, et al. Systematic prioritization of druggable mutations in 5, 000 genomes across 16 cancer types using a structural genomics-based approach. Mol Cell Proteomics 2016;15:642-56
131. Perola E. Minimizing false positives in kinase virtual screens. Proteins 2006;64:422-35
132. Ma DL, Chan DS, Leung CH. Drug repositioning by structurebased virtual screening. Chem Soc Rev 2013;42:2130-41
133. Deng N, Forli S, He P, et al. Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease. J Phys Chem B 2015;119:976-88
134. Li M, Kales SC, Ma K, et al. Balancing protein stability and activity in cancer: a new approach for identifying driver mutations affecting CBL ubiquitin ligase activation. Cancer Res 2016;76:561-71
135. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42
136. Glaeser RM. How good can cryo-EM become? Nat Methods 2015;13:28-32
137. Hodos RA, Kidd BA, Shameer K, et al. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016;8:186-210
138. Rubio-Perez C, Tamborero D, Schroeder MP, et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 2015;27:382-96
139. Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013;3:1416-29
140. Cheng F, Zhao J, Fooksa M, et al. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in human cancer genomes. J Am Med Inform Assoc 2016; doi: 10. 1093/jamia/ocw007
141. McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015;27:15-26
142. Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer 2015;15:473-83
143. Cheng F, Liu C, Shen B, et al. Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Syst Biol 2016; 10(Suppl 2):Sx
144. Isella C, Terrasi A, Bellomo SE, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 2015;47:312-9
145. Calon A, Lonardo E, Berenguer-Llergo A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320-9
146. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. Semin Cancer Biol 2013;23:279-85
147. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol 2013;23:286-92
148. Wang E, Zaman N, McGee S, et al. Predictive genomics: a cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol 2015;30:4-12
149. Masoudi-Nejad A, Wang E. Cancer modeling and network biology: accelerating toward personalized medicine. Semin Cancer Biol 2015;30:1-3
150. Wang J, Hu K, Guo J, et al. Combined inhibition of KRAS synthetic lethal partners, PLK1 and ROCK, suppresses KRASmutant cancers. Nat Commun 2016;7:11363
151. Cheng F, Li W, Zhou Y, et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model 2012;52:3099-105
152. Wang E. Understanding genomic alterations in cancer genomes using an integrative network approach. Cancer Lett 2013;340:261-9
153. Masoudi-NejadA, Bidkhori G, HosseiniAshtiani S, et al. Cancer systems biology and modeling: microscopic scale and multiscale approaches. Semin Cancer Biol 2015;30:60-9
154. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505:495-501
155. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-20
156. Errington TM, Iorns E, Gunn W, et al. An open investigation of the reproducibility of cancer biology research. Elife 2014;3: e04333;
157. Schneeweiss S. Learning from big health care data. N Engl J Med 2014;370:2161-3
158. Harrison C. GlaxoSmithKline opens the door on clinical data sharing. Nat Rev Drug Discov 2012;11:891-2
159. Peck RW. The right dose for every patient: a key step for precision medicine. Nat Rev Drug Discov 2016;15:145-6
160. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015;16:1324-34
161. Kleiman RJ, Ehlers MD. Data gaps limit the translational potential of preclinical research. Sci Transl Med 2016; 8:320ps1
162. Cheng F, Li W, Liu G, et al. In silico ADMET prediction: recent advances, current challenges and future trends. Curr Top Med Chem 2013;13:1273-89
163. Xie L, Bourne PE. Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. Front Pharmacol 2015;6:209
164. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 2007;7:213-21
165. Dang HX, Maher CA. Clonotyping for precision oncology. Drug Discov Today 2015;20:1464-9
166. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012;481:306-13
167. Martins VC, Busch K, Juraeva D, et al. Cell competition is a tumour suppressor mechanism in the thymus. Nature 2014;509:465-70
168. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2015;46:225-33
169. Sachlos E, Risueno RM, Laronde S, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012;149:1284-97
170. Zhao Y, Hu Q, Cheng F, et al. SoNar, a highly responsive NAD+/NADH sensor, allows high-throughput metabolic screening of anti-tumor agents. Cell Metab 2015;21:777-89
171. Kim P, Cheng F, Zhao J, et al. ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res 2016;44:D959-68
172. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014;32:479-84
173. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with wholegenome sequencing. Sci Transl Med 2012;4:162ra54
174. Fredriksson NJ, Ny L, Nilsson JA, et al. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet 2014;46:1258-63
175. Weinhold N, Jacobsen A, Schultz N, et al. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet 2014;46:1160-5
176. Wu SY, Lopez-Berestein G, Calin GA, et al. RNAi therapies: drugging the undruggable. Sci Transl Med 2014;6:240ps7
177. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348:56-61
178. Sanchez-Rivera FJ, Jacks T. Applications of the CRISPRCas9 system in cancer biology. Nat Rev Cancer 2015;15:387-95
179. Sachdeva M, Sachdeva N, Pal M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther 2015;22:509-17
180. Zelenay S, van der Veen AG, Bottcher JP, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015;162:1257-70
181. Kidd BA, Wroblewska A, Boland MR, et al. Mapping the effects of drugs on the immune system. Nat Biotechnol 2016;34:47-54